Skip to main content
. Author manuscript; available in PMC: 2016 May 10.
Published in final edited form as: Bone Marrow Transplant. 2015 Dec 7;51(3):333–343. doi: 10.1038/bmt.2015.301

Table 2.

Cytokine and CXCR4 antagonist effects on pDC mobilization and allograft content

Cytokine(s) Pre-clinical experience Clinical experience
G-CSF Mobilizes pDC48 PBSC have more pDC (lin−HLA-DR+CD11c−CD123+)
expansion/enrichment than BM32,33,41
GM-CSF Preferential expansion of myeloid DCs versus pDCs35,36,48
G+GM MSD PBSC: fewer pDCs and T cells, higher Th137
Plerixafor Induces p-preDC30 Induces plasmacytoid progenitors (CD34dimCD45RA+
CD123+)71
P+G Enrichment of conventional T cells, Tregs (CD4+/CD25high/
CD127low/FoxP3+) and pDCs (lin−CD11c−HLA-DR+CD123+)
in PB allograft43
Increased pDC content in murine splenocyte grafts128 		TCRαβ/CD19-depleted haploidentical PBSC grafts are
enriched for mDC and pDC42
Flt3 ligand Expands mDCs and pDCs58,129 and CD8α+DCs Endogenous FL correlates with DC and NK cell
reconstitution56
FL+G Progenipoietin-1 expands CD8α+DCs,48 mDCs and
pDCs103
FL+P Mobilized more pDCs than G alone55

Abbreviations: BM = bone marrow; DC = dendritic cell; FL = Flt3 ligand; G = G-CSF; GM = GM-CSF; mDCs = myeloid DCs; MSD = matched sibling donor; NA = unknown/not reported; NK = natural killer; P = plerixafor; PB = peripheral blood; p-preDC = plasmacytoid precursor DC.